Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.03
-6.3%
$0.03
$0.02
$0.14
$2.01M1.8994,829 shs270,617 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$3.48
+0.6%
$2.54
$1.61
$11.20
$221.54M0.86841,952 shs708,572 shs
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
$0.06
-1.0%
$0.11
$0.03
$10.79
N/A1.4247.79 million shs587.06 million shs
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
$0.53
$0.53
$0.53
$7.77
$1.56M1.1891,303 shsN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2.12
-2.3%
$2.20
$1.82
$3.09
$88.64M1.59141,600 shs26,946 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
+3.27%+9.23%+19.33%+9.65%-79.71%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
+4.22%+11.25%+30.08%+94.38%-60.93%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
+8.45%+6.73%-20.87%-91.68%-97.96%
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
0.00%0.00%0.00%0.00%-92.71%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
+3.83%+0.46%-2.69%+1.88%-13.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
0.3005 of 5 stars
0.03.00.00.00.61.70.0
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
1.5166 of 5 stars
3.61.00.00.01.11.70.0
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
2.5297 of 5 stars
3.32.00.00.01.12.51.3
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
0.2858 of 5 stars
0.03.00.00.00.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
0.00
N/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.11
Buy$18.50431.61% Upside
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
2.50
Moderate Buy$25.0041,776.05% Upside
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
2.25
Hold$10.001,798.97% Upside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest ORMP, NCNA, ONCT, LRMR, and GRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.00
6/24/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/A($2.41) per shareN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$2.69 per shareN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/A$1.34 per shareN/A
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
$790K1.97N/AN/A$10.19 per share0.05
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$1.34M64.63N/AN/A$3.61 per share0.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-$59.08M-$0.26N/AN/AN/AN/A-99.34%8/12/2025 (Estimated)
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$80.60M-$1.490.00N/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$24.28M-$7.020.00N/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$19.06M-$0.440.00N/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)

Latest ORMP, NCNA, ONCT, LRMR, and GRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.4877N/AN/AN/AN/AN/A
6/2/2025Q1 2025
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$0.0129-$0.63-$0.6171-$0.63N/AN/A
5/15/2025Q1 2025
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.03-$0.19-$0.16-$0.19N/A$2.00 million
4/30/2025Q1 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.42-$0.46-$0.04-$0.46N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/AN/A
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A
9.74
9.74
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
7.48
7.48
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/A
1.25
1.25
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
N/A
2.39
2.39
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
23.94
23.94

Institutional Ownership

CompanyInstitutional Ownership
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
50.77%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
44.00%
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
16.05%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
3075.46 million47.38 millionOptionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3064.03 million61.15 millionOptionable
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
306.08 million4.18 millionNot Optionable
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
302.96 million2.63 millionNo Data
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1040.85 million35.25 millionOptionable

Recent News About These Companies

Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance
Oramed Pharm Extends Stock Buyback Program
Oramed enters JV for insulin development and commercialization
Scilex announces early installment payment on senior secured promissory note

New MarketBeat Followers Over Time

Media Sentiment Over Time

Galera Therapeutics stock logo

Galera Therapeutics NASDAQ:GRTX

$0.03 0.00 (-6.34%)
As of 03:38 PM Eastern

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$3.48 +0.02 (+0.58%)
Closing price 04:00 PM Eastern
Extended Trading
$3.41 -0.07 (-1.90%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

NuCana stock logo

NuCana NASDAQ:NCNA

$0.06 0.00 (-1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$0.06 0.00 (-2.01%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Oncternal Therapeutics stock logo

Oncternal Therapeutics NASDAQ:ONCT

$0.53 0.00 (0.00%)
As of 04/29/2025

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$2.12 -0.05 (-2.30%)
Closing price 04:00 PM Eastern
Extended Trading
$2.13 +0.01 (+0.71%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.